Drugs / melrilimab
melrilimab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04366349 | Jul → Dec 2020 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02345928 | Aug 2014 → Mar 2017 | asthma, atopic eczema | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03393806 | Apr 2018 → Oct 2019 | asthma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT03207243 | Sep 2017 → Feb 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | melrilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04366349 ↗ |
| Known as | CNTO 7160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02345928 ↗ |
| Known as | GSK3772847 | “melrilimab (GSK3772847) 70 milligram (mg)” NCT04366349 ↗ |
| Modality | Monoclonal antibody | “anti-interleukin-33 receptor monoclonal antibody” PMID 32415720 ↗ Jun 2020 |
| Route | Intravenous | “administered intravenously (IV)” NCT02345928 ↗ |